vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and PAR TECHNOLOGY CORP (PAR). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $120.1M, roughly 1.4× PAR TECHNOLOGY CORP). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 14.4%). Over the past eight quarters, PAR TECHNOLOGY CORP's revenue compounded faster (30.9% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

PAR Technology Corp is a global provider of point-of-sale systems, restaurant management software, and integrated tech solutions. Its core segments serve food service, hospitality, and government security markets, offering cloud tools to streamline operations, enhance customer experiences, and boost efficiency for enterprise and small-to-medium clients.

ESPR vs PAR — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.4× larger
ESPR
$168.4M
$120.1M
PAR
Growing faster (revenue YoY)
ESPR
ESPR
+129.3% gap
ESPR
143.7%
14.4%
PAR
Faster 2-yr revenue CAGR
PAR
PAR
Annualised
PAR
30.9%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
PAR
PAR
Revenue
$168.4M
$120.1M
Net Profit
Gross Margin
41.2%
Operating Margin
50.6%
-15.0%
Net Margin
Revenue YoY
143.7%
14.4%
Net Profit YoY
EPS (diluted)
$0.32
$-0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
PAR
PAR
Q4 25
$168.4M
$120.1M
Q3 25
$87.3M
$119.2M
Q2 25
$82.4M
$112.4M
Q1 25
$65.0M
$103.9M
Q4 24
$69.1M
$105.0M
Q3 24
$51.6M
$96.8M
Q2 24
$73.8M
$78.2M
Q1 24
$137.7M
$70.1M
Net Profit
ESPR
ESPR
PAR
PAR
Q4 25
Q3 25
$-31.3M
$-18.2M
Q2 25
$-12.7M
$-21.0M
Q1 25
$-40.5M
$-24.4M
Q4 24
Q3 24
$-29.5M
$-19.8M
Q2 24
$-61.9M
$54.2M
Q1 24
$61.0M
$-18.3M
Gross Margin
ESPR
ESPR
PAR
PAR
Q4 25
41.2%
Q3 25
41.3%
Q2 25
45.4%
Q1 25
46.5%
Q4 24
42.9%
Q3 24
44.5%
Q2 24
41.0%
Q1 24
37.2%
Operating Margin
ESPR
ESPR
PAR
PAR
Q4 25
50.6%
-15.0%
Q3 25
-11.4%
-14.8%
Q2 25
8.6%
-15.4%
Q1 25
-34.0%
-15.2%
Q4 24
-6.4%
-15.6%
Q3 24
-31.0%
-15.7%
Q2 24
3.5%
-26.5%
Q1 24
52.5%
-38.2%
Net Margin
ESPR
ESPR
PAR
PAR
Q4 25
Q3 25
-35.9%
-15.3%
Q2 25
-15.4%
-18.7%
Q1 25
-62.2%
-23.4%
Q4 24
Q3 24
-57.2%
-20.5%
Q2 24
-83.9%
69.3%
Q1 24
44.3%
-26.1%
EPS (diluted)
ESPR
ESPR
PAR
PAR
Q4 25
$0.32
$-0.52
Q3 25
$-0.16
$-0.45
Q2 25
$-0.06
$-0.52
Q1 25
$-0.21
$-0.60
Q4 24
$-0.14
$-0.56
Q3 24
$-0.15
$-0.56
Q2 24
$-0.33
$1.60
Q1 24
$0.34
$-0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
PAR
PAR
Cash + ST InvestmentsLiquidity on hand
$167.9M
$80.1M
Total DebtLower is stronger
$394.0M
Stockholders' EquityBook value
$-302.0M
$825.1M
Total Assets
$465.9M
$1.4B
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
PAR
PAR
Q4 25
$167.9M
$80.1M
Q3 25
$92.4M
$93.0M
Q2 25
$86.1M
$85.7M
Q1 25
$114.6M
$92.2M
Q4 24
$144.8M
$108.6M
Q3 24
$144.7M
$118.4M
Q2 24
$189.3M
$142.5M
Q1 24
$226.6M
$72.5M
Total Debt
ESPR
ESPR
PAR
PAR
Q4 25
$394.0M
Q3 25
$393.4M
Q2 25
$392.8M
Q1 25
$392.3M
Q4 24
$368.4M
Q3 24
$466.7M
Q2 24
$378.7M
Q1 24
$378.2M
Stockholders' Equity
ESPR
ESPR
PAR
PAR
Q4 25
$-302.0M
$825.1M
Q3 25
$-451.4M
$838.0M
Q2 25
$-433.5M
$859.1M
Q1 25
$-426.2M
$852.0M
Q4 24
$-388.7M
$871.7M
Q3 24
$-370.2M
$692.7M
Q2 24
$-344.2M
$588.3M
Q1 24
$-294.3M
$526.4M
Total Assets
ESPR
ESPR
PAR
PAR
Q4 25
$465.9M
$1.4B
Q3 25
$364.0M
$1.4B
Q2 25
$347.1M
$1.4B
Q1 25
$324.0M
$1.4B
Q4 24
$343.8M
$1.4B
Q3 24
$314.1M
$1.3B
Q2 24
$352.3M
$1.1B
Q1 24
$373.1M
$1.0B
Debt / Equity
ESPR
ESPR
PAR
PAR
Q4 25
0.48×
Q3 25
0.47×
Q2 25
0.46×
Q1 25
0.46×
Q4 24
0.42×
Q3 24
0.67×
Q2 24
0.64×
Q1 24
0.72×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
PAR
PAR
Operating Cash FlowLast quarter
$45.2M
$-11.8M
Free Cash FlowOCF − Capex
$-12.5M
FCF MarginFCF / Revenue
-10.4%
Capex IntensityCapex / Revenue
0.0%
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-30.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
PAR
PAR
Q4 25
$45.2M
$-11.8M
Q3 25
$-4.3M
$8.4M
Q2 25
$-31.4M
$-6.6M
Q1 25
$-22.6M
$-17.2M
Q4 24
$-35.0M
$3.4M
Q3 24
$-35.3M
$8.8M
Q2 24
$-7.2M
$-13.8M
Q1 24
$53.8M
$-23.6M
Free Cash Flow
ESPR
ESPR
PAR
PAR
Q4 25
$-12.5M
Q3 25
$7.0M
Q2 25
$-7.4M
Q1 25
$-17.6M
Q4 24
$3.2M
Q3 24
$-35.5M
$8.4M
Q2 24
$-7.3M
$-14.2M
Q1 24
$53.8M
$-23.6M
FCF Margin
ESPR
ESPR
PAR
PAR
Q4 25
-10.4%
Q3 25
5.9%
Q2 25
-6.6%
Q1 25
-16.9%
Q4 24
3.0%
Q3 24
-68.7%
8.7%
Q2 24
-9.9%
-18.2%
Q1 24
39.0%
-33.7%
Capex Intensity
ESPR
ESPR
PAR
PAR
Q4 25
0.0%
0.7%
Q3 25
0.0%
1.1%
Q2 25
0.0%
0.7%
Q1 25
0.0%
0.4%
Q4 24
0.0%
0.2%
Q3 24
0.3%
0.4%
Q2 24
0.1%
0.5%
Q1 24
0.1%
0.1%
Cash Conversion
ESPR
ESPR
PAR
PAR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-0.26×
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

PAR
PAR

Subscription Service$76.1M63%
Hardware$27.8M23%
Professional Service$16.2M13%

Related Comparisons